Search

Your search keyword '"Horsfall, Leigh U"' showing total 31 results
Start Over Author "Horsfall, Leigh U"
31 results on '"Horsfall, Leigh U"'

5. Towards collaborative management of non‐alcoholic fatty liver disease: a ‘real‐world’ pathway for fibrosis risk assessment in primary care

Author

Hayward, Kelly L., primary, McKillen, Benjamin J., additional, Horsfall, Leigh U., additional, McIvor, Carolyn, additional, Liew, Katerina, additional, Sexton, Jo, additional, Johnson, Amy L., additional, Irvine, Katharine M., additional, Valery, Patricia C., additional, McPhail, Steven M., additional, Britton, Laurence J., additional, Rosenberg, William, additional, Weate, Ingrid, additional, Williams, Sue, additional, and Powell, Elizabeth E., additional

Published
2022
Full Text
View/download PDF

6. Serum CC-Chemokine Ligand 2 Is Associated with Visceral Adiposity but Not Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.

Author

Ferrari-Cestari, Michelle, Okano, Satomi, Patel, Preya J., Horsfall, Leigh U., Keshvari, Sahar, Hume, David A., Williams, Suzanne, Russell, Anthony, Powell, Elizabeth E., and Irvine, Katharine M.

Subjects
NON-alcoholic fatty liver disease, FATTY liver, HEPATIC fibrosis, LIVER diseases, TYPE 2 diabetes, OBESITY
Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is caused by ectopic fat accumulation in the liver as a consequence of metabolic perturbations associated with obesity, type 2 diabetes, dyslipidemia, and insulin resistance. People with NAFLD may develop metabolic and cardiovascular complications and/or liver-related complications, especially fibrosis and hepatocellular carcinoma, associated with high morbidity and mortality. Due to the high and increasing prevalence of NAFLD, there is an urgent need to identify people at risk of developing liver fibrosis and complications. CC-chemokine ligand 2 (CCL2) is chemokine that attracts inflammatory monocytes to stressed or injured tissues. Infiltrating inflammatory monocytes and CCL2 are strongly implicated in the pathogenesis of liver disease in animal models; however, evidence in patient cohorts is conflicting. Methods: We investigated associations between circulating CCL2 and clinical parameters, including fibrosis assessed by liver stiffness measurement, in a cohort of 250 NAFLD patients. We also measured fatty acid binding protein 2 (FABP2), a putative biomarker of intestinal permeability in patients with liver disease, since pro-inflammatory gut-derived microbial products may induce inflammatory chemokines such as CCL2. Results: Serum CCL2 levels were weakly associated with liver stiffness, but the association was no longer significant after accounting for age, diabetes, and BMI in a multivariable model. Consistent with this, girth and BMI were the strongest predictors of elevated circulating CCL2. Serum FABP2 was weakly, but significantly, correlated with CCL2, and negatively correlated with estimated glomerular filtration rate. Conclusion: Circulating CCL2 and FABP2 are associated with NAFLD comorbidities but not liver disease progression in patients with NAFLD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

7. Development and Evaluation of the Supportive Needs Assessment Tool for Cirrhosis (SNAC)

Author

Valery, Patricia C, Bernardes, Christina M, Stuart, Katherine A, Hartel, Gunter F, McPhail, Steven M, Skoien, Richard, Rahman, Tony, Clark, Paul J, Horsfall, Leigh U, Hayward, Kelly L, Gupta, Rohit, and Powell, Elizabeth E

Subjects
perceived needs, Patient Preference and Adherence, chronic liver disease, psychometric properties, Original Research, instrument validation
Abstract

Patricia C Valery,1,2 Christina M Bernardes,1 Katherine A Stuart,3 Gunter F Hartel,1 Steven M McPhail,4 Richard Skoien,5 Tony Rahman,6 Paul J Clark,7 Leigh U Horsfall,2,3 Kelly L Hayward,2 Rohit Gupta,8 Elizabeth E Powell2,3 1QIMR Berghofer Medical Research Institute, Herston, QLD, Australia; 2Centre for Liver Disease Research, Translational Research Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia; 3Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, QLD, Australia; 4Centre for Functioning and Health Research, Queensland Health and the School of Public Health and Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia; 5Department of Gastroenterology, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia; 6Gastroenterology & Hepatology Department, The Prince Charles Hospital, Chermside, QLD, Australia; 7Department of Gastroenterology and Hepatology, Mater Hospitals, Brisbane, QLD, Australia; 8Department of Gastroenterology and Hepatology, Sunshine Coast University Hospital, Birtinya, QLD, AustraliaCorrespondence: Patricia C ValeryQIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, AustraliaTel +61 7 33620376Email Patricia.Valery@qimrberghofer.edu.auBackground: We report the development and psychometric testing of a Supportive Needs Assessment tool for Cirrhosis (SNAC).Methods: The 50-item SNAC was administered to patients (n=465) diagnosed with cirrhosis recruited from five metropolitan hospitals in Queensland, Australia. Items were assessed for ceiling and floor effects, and exploratory factor analysis was used to assess the factor structure. Identified factors were assessed for internal consistency and convergent validity to validated psychosocial tools.Results: Exploratory factor analysis identified 4 factors (39 items), which together accounted for 49.2% of the total variance. The 39-item SNAC met the requirements of a needs assessment tool and identified a range of needs important to patients with cirrhosis that were grouped in four subscales: “Psychosocial issues”, “Practical and physical needs”, “Information needs”, and “Lifestyle changes”. Cronbach’s alpha values for the four subscales ranged from 0.64 to 0.92. Convergent validity was supported by a strong correlation between the total SNAC score and that of the Chronic Liver Disease Questionnaire (CLDQ; Spearman rho − 0.68; p< 0.001), and moderate correlations with the Distress Thermometer (Spearman rho 0.53; p< 0.001) and seven subscales of a generic health-related quality of life instrument (Short Form 36; Spearman rho ranged from − 0.48 to − 0.57; p< 0.001). The SNAC discriminated patient groups with respect to sex (p=0.013), age group (p< 0.001), and hospital admission status (admitted vs not; p< 0.001).Conclusion: These data provide initial evidence for the validity and reliability of the SNAC, an instrument designed to measure type and amount of perceived unmet practical and psychological needs of people diagnosed with cirrhosis.Keywords: chronic liver disease, perceived needs, instrument validation, psychometric properties

Published
2020

9. Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety

Author

Hayward, Kelly L., primary, Valery, Patricia C., additional, Patel, Preya J., additional, Li, Catherine, additional, Horsfall, Leigh U., additional, Wright, Penny L., additional, Tallis, Caroline J., additional, Stuart, Katherine A., additional, David, Michael, additional, Irvine, Katharine M., additional, Cottrell, Neil, additional, Martin, Jennifer H., additional, and Powell, Elizabeth E., additional

Published
2021
Full Text
View/download PDF

10. Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests

Author

Johnson, Amy L., primary, Hayward, Kelly L., additional, Patel, Preya, additional, Horsfall, Leigh U., additional, Cheah, Alvin Ee Zhiun, additional, Irvine, Katharine M., additional, Russell, Anthony W., additional, Stuart, Katherine A., additional, Williams, Sue, additional, Hartel, Gunter, additional, Valery, Patricia C., additional, and Powell, Elizabeth E., additional

Published
2021
Full Text
View/download PDF

12. Development and Evaluation of the Supportive Needs Assessment Tool for Cirrhosis (SNAC)

Author

Valery, Patricia C., Bernardes, Christina M., Stuart, Katherine A., Hartel, Gunter F., McPhail, Steven M., Skoien, Richard, Rahman, Tony, Clark, Paul J., Horsfall, Leigh U., Hayward, Kelly L., Gupta, Rohit, Powell, Elizabeth E., Valery, Patricia C., Bernardes, Christina M., Stuart, Katherine A., Hartel, Gunter F., McPhail, Steven M., Skoien, Richard, Rahman, Tony, Clark, Paul J., Horsfall, Leigh U., Hayward, Kelly L., Gupta, Rohit, and Powell, Elizabeth E.

Abstract

Background: We report the development and psychometric testing of a Supportive Needs Assessment tool for Cirrhosis (SNAC). Methods: The 50-item SNAC was administered to patients (n=465) diagnosed with cirrhosis recruited from five metropolitan hospitals in Queensland, Australia. Items were assessed for ceiling and floor effects, and exploratory factor analysis was used to assess the factor structure. Identified factors were assessed for internal consistency and convergent validity to validated psychosocial tools. Results: Exploratory factor analysis identified 4 factors (39 items), which together accounted for 49.2% of the total variance. The 39-item SNAC met the requirements of a needs assessment tool and identified a range of needs important to patients with cirrhosis that were grouped in four subscales: “Psychosocial issues”, “Practical and physical needs”, “Information needs”, and “Lifestyle changes”. Cronbach's alpha values for the four subscales ranged from 0.64 to 0.92. Convergent validity was supported by a strong correlation between the total SNAC score and that of the Chronic Liver Disease Questionnaire (CLDQ; Spearman rho −0.68; p<0.001), and moderate correlations with the Distress Thermometer (Spearman rho 0.53; p<0.001) and seven subscales of a generic health-related quality of life instrument (Short Form 36; Spearman rho ranged from −0.48 to −0.57; p<0.001). The SNAC discriminated patient groups with respect to sex (p=0.013), age group (p<0.001), and hospital admission status (admitted vs not; p<0.001). Conclusion: These data provide initial evidence for the validity and reliability of the SNAC, an instrument designed to measure type and amount of perceived unmet practical and psychological needs of people diagnosed with cirrhosis.

Published
2020

13. Development and Evaluation of the Supportive Needs Assessment Tool for Cirrhosis (SNAC)

Author

Valery,Patricia C, Bernardes,Christina M, Stuart,Katherine A, Hartel,Gunter F, McPhail,Steven M, Skoien,Richard, Rahman,Tony, Clark,Paul J, Horsfall,Leigh U, Hayward,Kelly L, Gupta,Rohit, Powell,Elizabeth E, Valery,Patricia C, Bernardes,Christina M, Stuart,Katherine A, Hartel,Gunter F, McPhail,Steven M, Skoien,Richard, Rahman,Tony, Clark,Paul J, Horsfall,Leigh U, Hayward,Kelly L, Gupta,Rohit, and Powell,Elizabeth E

Abstract

Patricia C Valery,1,2 Christina M Bernardes,1 Katherine A Stuart,3 Gunter F Hartel,1 Steven M McPhail,4 Richard Skoien,5 Tony Rahman,6 Paul J Clark,7 Leigh U Horsfall,2,3 Kelly L Hayward,2 Rohit Gupta,8 Elizabeth E Powell2,3 1QIMR Berghofer Medical Research Institute, Herston, QLD, Australia; 2Centre for Liver Disease Research, Translational Research Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia; 3Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, QLD, Australia; 4Centre for Functioning and Health Research, Queensland Health and the School of Public Health and Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia; 5Department of Gastroenterology, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia; 6Gastroenterology & Hepatology Department, The Prince Charles Hospital, Chermside, QLD, Australia; 7Department of Gastroenterology and Hepatology, Mater Hospitals, Brisbane, QLD, Australia; 8Department of Gastroenterology and Hepatology, Sunshine Coast University Hospital, Birtinya, QLD, AustraliaCorrespondence: Patricia C ValeryQIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, AustraliaTel +61 7 33620376Email Patricia.Valery@qimrberghofer.edu.auBackground: We report the development and psychometric testing of a Supportive Needs Assessment tool for Cirrhosis (SNAC).Methods: The 50-item SNAC was administered to patients (n=465) diagnosed with cirrhosis recruited from five metropolitan hospitals in Queensland, Australia. Items were assessed for ceiling and floor effects, and exploratory factor analysis was used to assess the factor structure. Identified factors were assessed for internal consistency and convergent validity to validated psychosocial tools.Results: Exploratory factor analysis identified 4 factors (39 items), which together accounted for 49.2% of the total variance. The 39-i

Published
2020

16. Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests.

Author

Johnson, Amy L., Hayward, Kelly L., Patel, Preya, Horsfall, Leigh U., Cheah, Alvin Ee Zhiun, Irvine, Katharine M., Russell, Anthony W., Stuart, Katherine A., Williams, Sue, Hartel, Gunter, Valery, Patricia C., and Powell, Elizabeth E.

Subjects
NON-alcoholic fatty liver disease, PROGNOSIS, HEPATIC fibrosis, FIBROSIS, ELECTRONIC health records
Abstract

It remains unclear whether screening for advanced fibrosis in the community can identify the subgroup of people with nonalcoholic fatty liver disease (NAFLD) at higher risk for development of liver‐related complications. We aimed to determine the prognostic value of baseline noninvasive fibrosis tests for predicting liver‐related outcomes and mortality in patients with NAFLD from type 2 diabetes (T2D) clinics or primary care. Patients (n = 243) who were screened for NAFLD with advanced fibrosis by using NAFLD fibrosis score (NFS), fibrosis 4 score (FIB‐4), enhanced liver fibrosis (ELF) test, and liver stiffness measurements (LSMs) were followed up for clinical outcomes by review of electronic medical records. During a median follow‐up of 50 months, decompensated liver disease or primary liver cancer occurred in 6 of 35 (17.1%) patients with baseline LSM > 13 kPa, 1 of 17 (5.9%) patients with LSM 9.5‐13 kPa, and in no patients with LSM < 9.5 kPa. No patient with low‐risk NFS developed liver decompensation or liver‐related mortality. Following repeat NFSs at the end of follow‐up, all patients with a liver‐related complication were in the high‐risk NFS category. Patients who developed liver‐related complications were also more likely to have baseline high‐risk FIB‐4 scores or ELF test ≥9.8 compared to patients who did not develop liver outcomes. Conclusion: Liver fibrosis risk stratification in non‐hepatology settings can identify the subset of patients at risk of liver‐related complications. Although the rate of development of a decompensation event or hepatocellular carcinoma was low (2.1% per year) in our patients with compensated cirrhosis (LSM > 13 kPa), these events are projected to lead to a substantial increase in NAFLD‐related disease burden over the next decade due to the high prevalence of NAFLD in people with obesity and T2D. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

18. Effectiveness of patient‐oriented education and medication management intervention in people with decompensated cirrhosis

Author

Hayward, Kelly L., primary, Valery, Patricia C., additional, Patel, Preya J., additional, Horsfall, Leigh U., additional, Wright, Penny L., additional, Tallis, Caroline J., additional, Stuart, Katherine A., additional, David, Michael, additional, Irvine, Katharine M., additional, Cottrell, W. Neil, additional, Martin, Jennifer H., additional, and Powell, Elizabeth E., additional

Published
2020
Full Text
View/download PDF

20. Medication‐Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention

Author

Hayward, Kelly L., primary, Patel, Preya J., additional, Valery, Patricia C., additional, Horsfall, Leigh U., additional, Li, Catherine Y., additional, Wright, Penny L., additional, Tallis, Caroline J., additional, Stuart, Katherine A., additional, Irvine, Katharine M., additional, Cottrell, W. Neil, additional, Martin, Jennifer H., additional, and Powell, Elizabeth E., additional

Published
2019
Full Text
View/download PDF

21. Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes

Author

Ramnath, Divya, primary, Irvine, Katharine M., additional, Lukowski, Samuel W., additional, Horsfall, Leigh U., additional, Loh, Zhixuan, additional, Clouston, Andrew D., additional, Patel, Preya J., additional, Fagan, Kevin J., additional, Iyer, Abishek, additional, Lampe, Guy, additional, Stow, Jennifer L., additional, Schroder, Kate, additional, Fairlie, David P., additional, Powell, Joseph E., additional, Powell, Elizabeth E., additional, and Sweet, Matthew J., additional

Published
2018
Full Text
View/download PDF

22. Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis

Author

Hayward, Kelly L, primary, Valery, Patricia C, additional, Martin, Jennifer H, additional, Karmakar, Antara, additional, Patel, Preya J, additional, Horsfall, Leigh U, additional, Tallis, Caroline J, additional, Stuart, Katherine A, additional, Wright, Penny L, additional, Smith, David D, additional, Irvine, Katharine M, additional, Powell, Elizabeth E, additional, and Cottrell, W Neil, additional

Published
2017
Full Text
View/download PDF

24. Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial

Author

Hayward, Kelly L., primary, Martin, Jennifer H., additional, Cottrell, W. Neil, additional, Karmakar, Antara, additional, Horsfall, Leigh U., additional, Patel, Preya J., additional, Smith, David D., additional, Irvine, Katharine M., additional, Powell, Elizabeth E., additional, and Valery, Patricia C., additional

Published
2017
Full Text
View/download PDF

25. Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease

Author

Patel, Preya J., primary, Smith, David, additional, Connor, Jason P., additional, Horsfall, Leigh U., additional, Hayward, Kelly L., additional, Hossain, Fabrina, additional, Williams, Suzanne, additional, Johnson, Tracey, additional, Stuart, Katherine A., additional, Brown, Nigel N., additional, Saad, Nivene, additional, Clouston, Andrew D., additional, Irvine, Katharine M., additional, Russell, Anthony W., additional, Valery, Patricia C., additional, and Powell, Elizabeth E., additional

Published
2017
Full Text
View/download PDF

26. Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers

Author

Irvine, Katharine M., primary, Wockner, Leesa F., additional, Hoffmann, Isabell, additional, Horsfall, Leigh U., additional, Fagan, Kevin J., additional, Bijin, Veonice, additional, Lee, Bernett, additional, Clouston, Andrew D., additional, Lampe, Guy, additional, Connolly, John E., additional, and Powell, Elizabeth E., additional

Published
2016
Full Text
View/download PDF

28. The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease

Author

Irvine, Katharine M., primary, Wockner, Leesa F., additional, Shanker, Mihir, additional, Fagan, Kevin J., additional, Horsfall, Leigh U., additional, Fletcher, Linda M., additional, Ungerer, Jacobus P. J., additional, Pretorius, Carel J., additional, Miller, Gregory C., additional, Clouston, Andrew D., additional, Lampe, Guy, additional, and Powell, Elizabeth E., additional

Published
2015
Full Text
View/download PDF

29. Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers

Author

Fagan, Kevin J, primary, Irvine, Katharine M, additional, McWhinney, Brett C, additional, Fletcher, Linda M, additional, Horsfall, Leigh U, additional, Johnson, Lambro, additional, O’Rourke, Peter, additional, Martin, Jennifer, additional, Scott, Ian, additional, Pretorius, Carel J, additional, Ungerer, Jacobus PJ, additional, and Powell, Elizabeth E, additional

Published
2014
Full Text
View/download PDF

31. Towards collaborative management of non‐alcoholic fatty liver disease: a ‘real‐world’ pathway for fibrosis risk assessment in primary care.

Author

Hayward, Kelly L., McKillen, Benjamin J., Horsfall, Leigh U., McIvor, Carolyn, Liew, Katerina, Sexton, Jo, Johnson, Amy L., Irvine, Katharine M., Valery, Patricia C., McPhail, Steven M., Britton, Laurence J., Rosenberg, William, Weate, Ingrid, Williams, Sue, and Powell, Elizabeth E.

Abstract

Background Aims Methods Results Conclusion The optimal strategy to support primary care practitioners (PCP) to assess fibrosis severity in non‐alcoholic fatty liver disease (NAFLD) and thereby make appropriate management decisions remains unclear.To examine the feasibility of using a two‐step pathway that combined simple scores (NAFLD Fibrosis Score and Fibrosis‐4 Index) with transient elastography (FibroScan) to streamline NAFLD referrals from a ‘routine’ primary care population to specialist hepatology management clinics (HMC).The two‐step ‘Towards Collaborative Management of NAFLD’ (TCM‐NAFLD) fibrosis risk assessment pathway was implemented at two outer metropolitan primary healthcare practices in Brisbane. Patients aged ≥18 years with a new or established PCP‐diagnosis of NAFLD were eligible for assessment. The pathway triaged patients at ‘high risk’ of clinically significant fibrosis to HMC for specialist review, and ‘low risk’ patients to receive ongoing management and longitudinal follow up in primary care.A total of 162 patient assessments between June 2019 and December 2020 were included. Mean age was 58.7 ± 11.7 years, 30.9% were male, 54.3% had type 2 diabetes or impaired fasting glucose, and mean body mass index was 34.2 ± 6.9 kg/m2. A total 122 patients was considered ‘low risk’ for clinically significant fibrosis, two patients had incomplete assessments and 38 (23.5%) were triaged to HMC. Among 31 completed HMC assessments to date, 45.2% were considered to have clinically significant (or more advanced) fibrosis, representing 9.2% of 153 completed assessments.Implementation of the two‐step TCM‐NAFLD pathway streamlined hepatology referrals for NAFLD and may facilitate a more cost‐effective and targeted use of specialist hepatology resources. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results